Edwards Lifesciences Corp
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, and
CONSOLIDATED BALANCE SHEETS
(in millions, except par value)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $1,144.0 | $769.0 |
| Short-term investments (Note 7) | 500.5 | 446.3 |
| Accounts receivable, net of allowances of $8.3 and $7.9, respectively | 775.1 | 643.0 |
| Other receivables | 61.8 | 56.1 |
| Inventories (Note 5) | 1,168.2 | 875.5 |
| Prepaid expenses | 146.8 | 110.0 |
| Other current assets | 239.3 | 195.9 |
| Total current assets | 4,035.7 | 3,095.8 |
| Long-term investments (Note 7) | 583.9 | 1,239.0 |
| Property, plant, and equipment, net (Note 5) | 1,749.4 | 1,632.8 |
| Operating lease right-of-use assets (Note 6) | 94.0 | 92.3 |
| Goodwill (Note 10) | 1,253.5 | 1,164.3 |
| Other intangible assets, net (Note 10) | 428.4 | 285.2 |
| Deferred income taxes | 754.6 | 484.0 |
| Other assets | 463.7 | 299.1 |
| Total assets | $9,363.2 | $8,292.5 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable | $201.4 | $201.9 |
| Accrued and other liabilities (Note 5) | 969.1 | 795.0 |
| Operating lease liabilities (Note 6) | 24.9 | 25.5 |
| Total current liabilities | 1,195.4 | 1,022.4 |
| Long-term debt (Note 11) | 597.0 | 596.3 |
| Contingent consideration liabilities (Note 12) | — | 26.2 |
| Taxes payable (Note 18) | 80.6 | 143.4 |
| Operating lease liabilities (Note 6) | 73.0 | 69.5 |
| Uncertain tax positions (Note 18) | 339.3 | 267.5 |
| Litigation settlement accrual (Note 3) | 94.2 | 143.0 |
| Other liabilities | 264.3 | 217.5 |
| Total liabilities | 2,643.8 | 2,485.8 |
| Commitments and contingencies (Notes 6, 11, and 19) | ||
| Stockholders' equity (Note 15) | ||
| Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | — | — |
| Common stock, $1.00 par value, 1,050.0 shares authorized, 650.5 and 646.3 shares issued, and 601.1 and 608.3 shares outstanding, respectively | 650.5 | 646.3 |
| Additional paid-in capital | 2,274.4 | 1,969.3 |
| Retained earnings | 8,992.4 | 7,590.0 |
| Accumulated other comprehensive loss (Note 16) | (242.8) | (254.9) |
| Treasury stock, at cost, 49.4 and 38.0 shares, respectively | (5,024.5) | (4,144.0) |
| Total Edwards Lifesciences Corporation stockholders' equity | 6,650.0 | 5,806.7 |
| Noncontrolling interest (Note 9) | 69.4 | — |
| Total stockholders' equity | 6,719.4 | 5,806.7 |
| Total liabilities and stockholders' equity | $9,363.2 | $8,292.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.